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The present study examined the roles of peroxisome
proliferator-activated receptors (PPAR) in activation of
hepatic stellate cells (HSC), a pivotal event in liver fi-
brogenesis. RNase protection assay detected mRNA for
PPARg1 but not that for the adipocyte-specific g2 iso-
form in HSC isolated from sham-operated rats, whereas
the transcripts for neither isoforms were detectable in
HSC from cholestatic liver fibrosis induced by bile duct
ligation (BDL). Semi-quantitative reverse transcriptase-
polymerase chain reaction confirmed a 70% reduction in
PPARg mRNA level in HSC from BDL. Nuclear extracts
from BDL cells showed an expected diminution of bind-
ing to PPAR-responsive element, whereas NF-kB and
AP-1 binding were increased. Treatment of cultured-
activated HSC with ligands for PPARg (10 mM 15-deoxy-
D12,14-PGJ2 (15dPGJ2); 0.1;10 mM BRL49653) inhibited
DNA and collagen synthesis without affecting the cell
viability. Suppression of HSC collagen by 15dPGJ2 was
abrogated 70% by the concomitant treatment with a
PPARg antagonist (GW9662). HSC DNA and collagen
synthesis were inhibited by WY14643 at the concentra-
tions known to activate both PPARa and g (>100 mM) but
not at those that only activate PPARa (<10 mM) or by a
synthetic PPARa-selective agonist (GW9578). 15dPGJ2
reduced a1(I) procollagen, smooth muscle a-actin, and
monocyte chemotactic protein-1 mRNA levels while in-
ducing matrix metalloproteinase-3 and CD36. 15dPGJ2
and BRL49653 inhibited a1(I) procollagen promoter ac-
tivity. Tumor necrosis factor a (10 ng/ml) reduced
PPARg mRNA, and this effect was prevented by the
treatment with 15dPGJ2. These results demonstrate
that HSC activation is associated with the reductions in
PPARg expression and PPAR-responsive element bind-
ing in vivo and is reversed by the treatment with PPARg
ligands in vitro. These findings implicate diminished
PPARg signaling in molecular mechanisms underlying
activation of HSC in liver fibrogenesis and the potential
therapeutic value of PPARg ligands for liver fibrosis.
Hepatic stellate cells (HSC)1 are vitamin A-storing, perisi-
nusoidal pericytes that serve as the major source of extracel-
lular matrices in liver fibrosis (1). The most intriguing aspect of
the involvement of HSC in liver fibrogenesis is that HSC un-
dergo phenotypic changes often characterized as “myofibroblas-
tic activation” (1–3). During this activation, HSC lose their
intracellular vitamin A content (4, 5), induce MMP-2 and -3 to
facilitate matrix remodeling (6, 7), proliferate (8, 9), up-regu-
late expression of matrix proteins (10, 11), tissue inhibitors of
metalloproteinase (TIMP) (12), a-smooth muscle actin (5, 13),
andendothelinreceptors(14,15),andundergoactincytoskeleton-
dependent alterations in morphology (16).
To understand the molecular basis of the multifaceted cellu-
lar changes in HSC activation, increasing efforts have been
made to characterize alterations in specific gene regulation or
intracellular signaling that may confer some of the activation
events. Such examples include up-regulation of autocrine cyto-
kines such as TGF-b (5, 8, 11), TGF-a (8), interleukin-10 (17),
and their receptors (18, 19). In particular, the evidence for the
pivotal role of TGF-b in liver fibrogenesis is compelling, as
exemplified by a recent demonstration of amelioration of ex-
perimental liver fibrosis by an adenovirus vector expressing
the dominant negative TGF-b type II receptor (20). Early genes
induced during activation of HSC may be associated with in-
duction of this fibrogenic cytokine. One such example is a
Kruppel-like zinc finger transcription factor, Zf9, which was
recently shown to transactivate promoters for both TGF-b1 and
type I and II TGF-b receptors (21). Alternatively, the changes
in the cellular content of retinoids may favor induction of
TGF-b. Depletion of retinoids occurs in activation of HSC both
in culture (4) and in vivo (5) and appears to precede induction
of TGF-b1 and matrix genes (5). All-trans and 9-cis retinoic
acids (RA), biologically active metabolites of vitamin A, are also
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depleted in activated HSC isolated from experimental biliary
liver fibrosis (22). RAR and RXR serve as nuclear receptors for
RA, and their levels are also reduced in activated HSC (22).
RAR and RXR are known to antagonize AP-1 promoter activi-
ties of TGF-b1 (23) and metalloproteinases (24, 25) in a RA-de-
pendent manner. Thus, it is plausible that deficiencies of RA,
RAR, and RXR may permissively up-regulate AP-1 activity in
activated HSC via suppressed RA-mediated, negative cross-
coupling of this transcription factor. In fact the treatment of
cultured HSC with all-trans RA causes suppression of cell
proliferation, collagen, and TGF-b production (26). On the con-
trary, 9-cis RA (27) and 9,13-di-cis-RA (28) are shown to acti-
vate latent TGF-b via up-regulation of tissue plasminogen ac-
tivator. These conflicting effects may be due to the recently
demonstrated differential effects of the RA isomers on HSC (29)
or complex responses rendered by RA, particularly via RXR.
RXR heterodimerizes with the members of the steroid/thy-
roid hormone receptor superfamily, such as vitamin D receptor,
thyroid hormone receptor, peroxisome proliferator-activated
receptor (PPAR), liver X receptor (LXR), and farnesoid X-acti-
vated receptor (FXR) (30). Since RXR serves as a ligand-de-
pendent, active partner for some of these receptors such as
PPAR and LXR, the reduced levels of 9-cis RA and RXR, as
previously shown by us in HSC from cholestatic livers (22), may
limit activities of the transcription factors. In particular, we
hypothesized whether PPARg expression might be suppressed
in activated HSC. This hypothesis was inspired by the recent
demonstration of leptin induction in culture-activated HSC
(31). Leptin, a 16-kDa protein most exclusively expressed in
adipose tissue, is the product of the ob gene, which suppresses
food intake, increases metabolic rate, and reduces fat depot size
(See Ref. 32 for review). The deficiency of leptin or its receptor
is associated with the obesity in mice and human. Thus, the
finding that leptin expression is induced in culture-activated
HSC suggests the possibility that HSC may share the adipocyte
phenotype. In fact, quiescent HSC is characterized by ample
intracellular storage of lipids including fat-soluble vitamin A,
and activation of HSC causes depletion of lipid droplets and
transdifferentiation to myofibroblastic phenotype. These
changes resemble transdifferentiation of 3T3-L1 cells that pos-
sess the potential to differentiate into either fibroblasts (prea-
dipocytes) or adipocytes. With appropriate stimulation with
fetal calf serum, dexamethasone, insulin, etc., 3T3-L1 cells
undergo adipocyte differentiation driven by transcription fac-
tors such as PPARg, C/EBP, and ADD1/SREBP1(32). Con-
versely, suppressed activities of these transcription factors re-
sult in fibroblastic differentiation (32).
In the present study, we have examined expression of PPARg
isoforms in quiescent HSC isolated from normal rats and acti-
vated HSC from experimental biliary liver fibrosis. RNase pro-
tection assay revealed expression of g1 isoform in quiescent
HSC but not that of the adipocyte-specific g2 form, providing no
support to the hypothesis that HSC share the adipogenic phe-
notype. However, we disclosed marked reductions in expres-
sion of PPARg and PPAR response element (PPRE) binding in
the in vivo activated HSC. Furthermore, the treatment of cul-
ture-activated HSC with PPARg ligands (15dPGJ2 and
BRL49653) reversed biochemical features of HSC activation. In
particular, the ligands inhibited a1(I) procollagen promoter
activity, its mRNA expression, and collagen production by the
cells, and the inhibition by 15dPGJ2 was shown to be blocked
by a PPARg antagonist, confirming the involvement of PPARg.
These results suggest the pivotal roles of PPARg in molecular
regulation of HSC activation in liver fibrogenesis.
MATERIALS AND METHODS
Bile Duct Ligation—Bile duct ligation was performed using male
Wister rats weighing 550–650 g by aseptic ligation and scission of the
common bile duct (BDL) as described previously (22). Another group of
rats was sham-operated by exposing the common bile duct without
ligation or scission as a control (sham). The animal protocol in this
study was approved by the Institutional Care and Use Committee of the
University of Southern California.
HSC Isolation—Hepatic stellate cells were isolated from BDL, sham,
and normal rats by the method previously described (5, 22). Briefly, the
liver was perfused in situ first with calcium-free minimum essential
medium (Life Technologies, Inc.) followed by 0.62% Pronase (Roche
Molecular Biochemicals) and 0.0125% type IV collagenase (Sigma) in
Dulbecco’s modified Eagle’s medium/F-12 (Life Technologies, Inc.). For
rats cholestatic for 19 days, a mixture of 0.02% type IV collagenase and
0.04% type I collagenase (Roche Molecular Biochemicals) was used
because of the extremely fibrotic condition of the livers. The liver was
carefully removed and minced with scissors. The digested liver was
further incubated in a shaker-incubator with 0.035% pronase and 62.5
units/ml DNase (Sigma) in Dulbecco’s modified Eagle’s medium/F-12 at
37 °C for 30 min. It was then filtered through gauze, and parenchymal
cells were removed by low speed centrifugation. The resultant super-
natant was laid on top of the four density gradients (1.035, 1.045, 1.058,
and 1.085) of arabinogalactan (LARCOLL, Sigma) and centrifuged at
21,400 rpm for 45 min at 25 °C using Beckman SW41-Ti rotor (Beck-
man Instruments). The interface between the media and the density
1.035 was recovered as a pure HSC fraction. The purity of isolated HSC
were examined by phase contrast microscopy and ultraviolet-excited
fluorescence microscopy and the viability by trypan blue exclusion.
Primary Culture of HSC—Isolated HSC from normal rats were cul-
tured in six-well plates with RPMI 1640 supplemented with 10% fetal
bovine serum, 100 units/ml streptomycin, and 100 units/ml penicillin
and amphotericin B (Life Technologies, Inc.). The cultures were main-
tained for 3–4 days or 6–7 days before tested for effects of PPAR
ligands. By these time points the cells began to show or already showed
morphological features of culture-activated HSC as described previ-
ously (1, 13). For DNA and collagen synthesis analyses, HSC were
seeded in 24-well plates with the aforementioned media. For morpho-
logical examination of HSC, the cells were cultured onto 10-mm2 cov-
erslips placed in 6-well plates for 7 days before testing the effects of
15dPGJ2 or BRL49653. To assess the effects of PPARa and PPARg
ligands on HSC in vitro, cultured HSC were washed twice with phos-
phate-buffered saline and incubated in serum-free media. The cells
were then treated with 15dPGJ2 (1;10 mM, Biomol, Plymouth Meeting,
PA), BRL49653 (0.1;10 mM, a gift from Glaxo Wellcome, Research
Triangle Park, NC), or WY14643 (1;250 mM, Biomol) or vehicle alone
(Me2SO for WY14643 and BRL49653 or ethanol for 15dPGJ2) for 18 h.
These cells were examined for DNA and collagen synthesis, morpholog-
ical analysis, and mRNA expression for various activation maker genes
as described below. To test the PPARg dependence of 15dPGJ2-medi-
ated effect on HSC collagen synthesis, the cells were concomitantly
incubated with a PPARg antagonist, GW9662 (33, 34).
DNA and Collagen Synthesis—DNA synthesis was determined as
incorporation of [3H]thymidine (10 mCi/ml) into HSC DNA as described
previously (9). Collagen synthesis was determined by incorporation of
[3H]proline (10 mCi/ml) into collagenase-sensitive peptides in the pres-
ence of ascorbic acid (50 mg/ml) and b-aminopropionitrile fumarate (50
mg/ml) as described (17).
RNA and Nuclear Protein Extraction—Total RNA was extracted
from isolated HSC by the guanidinium-phenol-chloroform method of
Chomczynski and Sacchi (35) and nuclear protein by the method of
Schreiber et al. (36). RNA and nuclear protein concentrations were
determined by the absorbance at 260 nm and a Bradford assay,
respectively.
RNase Protection Assay and Reverse Transcription-PCR—RNase
protection assay was performed for PPARg1 and -g2 transcripts using
an approach previously described (37). A partial PPARg cDNA was
generated by RT-PCR using the rat PPARg2-specific primers, which
amplified a region that includes 90 base pairs of the PPARg2 transcript
and 185 base pairs common to both PPARg1 and g2. The cDNA was
ligated into the PGEM-3 vector for generation of an antisense RNA
probe. The assay was performed using 32P-labeled RNA probe, 5 or 10
mg of RNA from HSC isolated from BDL and sham, and a RNase
protection assay kit from Torrey Pines Biolabs, Inc. (San Diego, CA). As
a control, L32 was used. For RT-PCR analysis for HSC activation
marker genes, 2 mg of total RNA was transcribed into cDNA using 600
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units of Moloney murine leukemia virus reverse transcriptase and
oligo(dT)15 as a primer at 37 °C for 60 min. The synthesized cDNA were
amplified using specific sets of primers for PPARa, (CCTTTTTGTGG-
CTGCTAT, TCCCTGCTCTCCTGTATG), PPARg (ATTCTGGCCCACC-
AACTTCGG, TGGAAGCCTGATGCTTTATCCCCA), smooth muscle
a-actin (a-SMA) (TGTGCTGGACTCTGGAGATG, GATCACCTGCCCA-
TCAGG), a1(I) procollagen (17), MMP-3 (ACGCACAACTTCAAGCTG-
CC, TTAATTCCGAAGACGCCAGAAC), MMP-13 (17), MCP-1 (GAAC-
CAGGATTCACAGAG, ATGCAGGTATATGTCACGC), CD-36 (GGAG-
GCATTCTCATGCCGGTTGGAG, TGAGAACTGTGAAGTTGTCATTC-
TC), and b-actin (22). Each PCR mixture contained 0.4 mM of a set of
specific primers, 0.2 mM each dNTP, 2.5 units Taq polymerase, 1.5 mM
MgCl2, and 2 ml of cDNA except for b-actin, for which 1 ml was used.
PCR procedure consisted of 20 cycles (a-SMA, a1(I) procollagen, MCP-1,
and b-actin) or 30–35 cycles (PPARa, PPARg, MMP-3, and MMP-13) of
denaturation at 94 °C for 45 s, annealing at 55 °C for 30 s, extension at
72 °C for 90 s, with initial denaturation of sample cDNA at 94 °C for 3
min before PCR and additional extension period of 10 min after the last
cycle. PCR products were run on 1.5% agarose gel containing 0.004%
ethidium bromide and visualized under UV transiluminator. The den-
sitometric analysis of PCR products was performed by the computer
software, ImageQuant for Power Macintosh v1.2 (Molecular Dynamics),
and standardized by the b-actin.
Electrophoretic Mobility Shift Assay—Nuclear protein extract (10–20
mg) was incubated with a reaction mixture (20 mM HEPES, pH 7.6, 100
mM KCl, 0.2 mM EDTA, 2 mM dithiothreitol, 20% glycerol, 200 mg/ml
poly(dI-dC)) on ice for 10 min. One to two ng of a 32P-labeled double-
stranded ARE-7 (PPRE) (38), AP-1 (22), or NF-kB (39) oligonuleotides
were added and incubated for an additional 20 min. The reaction
mixture was then resolved on a 6% nondenaturing polyacrylamide gel
in 0.53 TBE (45 mM Tris, 45 mM boric acid, 1 mM EDTA). The gel was
dried and subjected to autoradiography at 280 °C. For supershift assay,
we have used antisera against PPARg (kindly provided by Dr. Ronald
M. Evans, The Salk Institute, San Diego, CA) and polyclonal antibodies
against P65, P50, c-Fos, and c-Jun (Santa Cruz Biotechnology, Santa
Cruz, CA).
Transfection and Reporter Gene Assay—To examine whether PPARa
and -g ligands have effects on collagen gene promoter activity, cultured
HSC after the first passage were co-transfected with a collagen reporter
gene plasmid (pGLCO2) that contains 2,200 base pairs of the murine
a1(I) collagen gene 59-flanking region ligand to the luciferase reporter
gene (40) and a PPARg expression vector (kindly provided by Dr. Ron
Evans, The Salk Institute, San Diego, CA and Dr. Henry Sucov, Insti-
tute for Genetic Medicine, University of Southern California, Los An-
geles, CA). The cells were serum-starved (0.2% fetal calf serum, 24 h)
and then treated with 15dPGJ2 (1 and 10 mM), BRL49653 (10 mM) for
24 h before their lysate was collected for luciferase assay. Liposomes
were prepared using 1 mg of the reporter gene plasmid and 2 mg of the
expression vector along with LipofectAMINE reagent (Life Technolo-
gies, Inc.) The cells were incubated with the liposomes for 3 h, the
liposome mixture was removed, and fresh medium containing 10% fetal
calf serum was added for incubation for 15 h.
Morphological Analysis—To investigate the effects of PPARg ligand
on the actin cytoskeleton and HSC morphology, cells cultured onto glass
coverslips were exposed to 15dPGJ2 (1 and 10 mM) BRL49653 (1 and 10
mM), or carrier (ethanol). Actin stress fibers and focal adhesion com-
plexes were stained, and differential interference contrast images were
acquired as described previously (16). Briefly, stress fibers were labeled
with rhodamine-phalloidin, which binds to filamentous actin with high
specificity. Focal adhesion complexes were labeled with an antibody
directed against vinculin, a prominent component of the complex. A
fluorescein-labeled secondary antibody was used to stain the focal ad-
hesion complexes. Standard rhodamine and fluorescein filters (Chroma,
Brattleboro, VT) were employed. Epifluorescence and differential inter-
ference contrast images were acquired digitally. The morphological
analysis was performed by a blinded observer.
Staining for Necrosis and Apoptosis—To assess the effects of PPAR
ligands on cultured HSC viability, we performed SYTOX® green nucleic
acid staining (Molecular Probes, Inc. Eugene, OR) for necrosis and
Hoechst staining (Sigma) for apoptosis. HSC were cultured in 24-well
plates, treated with 15dPGJ2 (1;10 mM), BRL49653 (0.1;10 mM), or
WY14643 (100;250 mM) for 18 h from day 6 to day 7 of primary
cultures, washed gently with phosphate-buffered saline, and stained
according to the manufacturer’s suggested protocols. Two hundred cells
were analyzed in triplicates, and the incidence of necrosis and apoptosis
was expressed as the percentage of total cells examined.
Statistical Analysis—All data are expressed as means 6 S.E. The
significance for the difference between the groups was assessed using
Student’s t test.
RESULTS
PPARg Isoform Expression by HSC—Using a sensitive
RNase protection assay that allowed simultaneous quantifica-
tion of mRNA for both isoforms (37), we first examined expres-
sion of PPARg isoforms in freshly isolated normal and in vivo
activated HSC. As shown in Fig. 1, the assay detected abun-
dant expression of both g2 and g1 isoforms in RNA extracted
from rat epididymal fat (second lane). Liver tissue also ex-
pressed both isoforms but at much less levels (third lane). HSC
isolated from sham-operated rats, expressed only g1 mRNA
(fourth lane), and neither g1 nor g2 isoform was detectable in
HSC from 1-week BDL animals (fifth lane). We also tested up
to 10 mg of RNA for HSC from sham and BDL rats with
basically same results. Thus, these data demonstrated that
normal rat HSC express g1 mRNA, the isoform that is gener-
ally expressed in various tissues (37), but not the g2 isoform,
which is more selectively expressed in adipocytes. Further-
more, HSC from experimental biliary liver fibrosis (BDL) ap-
peared to be depleted of PPARg1 expression.
Diminished PPAR Expression by in Vivo Activated HSC—
Since the RNase protection assay failed to detect PPARg tran-
scripts in HSC from 1-week BDL, we next performed RT-PCR
to amplify the mRNA. This PCR did not distinguish the iso-
forms and amplified both. After 35 cycles, we were able to
detect PPARg in HSC from BDL. However, the level of PPARg
expression was reduced as compared with HSC from sham,
whereas mRNA expression for a1(I) collagen and a-SMA was
induced (Fig. 2A). Next, we examined HSC from BDL rats at 19
days after the surgery. Similarly, the PPARg level was conspic-
uously reduced in BDL animals (Fig. 2B). In addition, PPARa
mRNA level was also decreased in these animals (Fig. 2B).
Semi-quantitative analysis of the PCR densitometric data re-
vealed approximately 70–80% reduction in PPARa and PPARg
mRNA expression in HSC from the 19-day BDL animals (Fig.
2C).
FIG. 1. RNase protection assay for PPARg1 and -g2 tran-
scripts. RNase protection assay was performed on samples (5 mg each)
extracted from rat epididymal fat (first lane), rat liver (third lane),
hepatic stellate cells isolated from a sham-operated rat (HSC-sham,
fourth lane), and hepatic stellate cells from a 7-day bile duct-ligated rat
(HSC-BDL, fifth lane). Note the abundant expression of both forms of
PPARg in the fat sample. Even though the level of expression is much
less, the liver RNA also contains both forms of PPARg. However, only
the PPARg1 transcript, but not an adipocyte specific PPARg2, is de-
tected in the RNA sample from HSC-sham, and the PPARg1 expression
is diminished in HSC-BDL.
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Reduced PPRE Binding in HSC from BDL Animals—To
assess the consequence of the observed depletion of PPARg and
-a mRNA levels, nuclear extracts were prepared from HSC
from 19-day BDL and sham animals, and electrophoretic mo-
bility shift assay was performed for PPRE binding. For this
assay, we selected an ARE-7 probe (PPRE from aP2 gene) that
preferentially binds PPARg over PPARa (38). As shown in Fig.
3, PPRE binding was appreciably decreased in HSC from BDL
(upper panel). The specificity of this binding was supported by
competition with 3500 excess cold probe (data not shown) and
a supershift assay using antibodies against PPARg. The latter
technique demonstrated a diminution of the DNA binding with
sham nuclear extracts and the appearance of a supershifted
band (arrow, last lane, Fig. 3, upper panel), whereas non-
immune serum did not affect the PPAR binding (data not
shown). In contrast, NF-kB and AP-1 binding by the nuclear
extracts from BDL HSC were conspicuously increased (lower
panels). The specificity of NF-kB and AP-1 binding was sup-
ported by competition with excessive cold probe as well as
supershift assays (data not shown), as previously performed in
our laboratory (22, 39). Thus, these results demonstrate that
“activated” HSC from the cholestatic liver fibrosis model are
depleted of PPARa and -g mRNA and PPRE binding and sug-
gest the potential significance of these changes in activation of
HSC.
Effects of PPAR Ligands on HSC Viability in Culture—To
test the potential role of PPAR in regulating activation of HSC,
we next investigated the in vitro effects of PPAR ligands on
culture-activated HSC. For these experiments, we first exam-
ined the effects of PPAR ligands on HSC viability. We tested
the ranges of 15dPGJ2 (1;10 mM) BRL49653 (0.1;10 mM), and
WY14643 (1;250 mM) concentrations that had been used in
earlier studies on other cell types (41–44). Staining of the cells
for necrosis (SYTOX green nucleic acid staining) or apoptosis
(Hoechst staining) showed no induction of either form of cell
death by incubating the cells with these concentrations of
15dPGJ2, BRL49653, or WY14643 for 24 h. However, we ob-
served a significant increase in the incidence of cell necrosis to
6.90 6 2.75% in the cells treated with 100 mM 15dPGJ2 as
compared with 0.83 6 0.29% in the vehicle (ethanol)-treated
cells. Based on these results, we used the non-cytotoxic concen-
trations of 15dPGJ2 (1 and 10 mM), BRL49653 (0.1;10 mM), and
WY14643 (10 100, and 250 mM) in the subsequent biochemical
experiments.
Effects of PPAR Ligands on HSC DNA and Collagen Synthe-
sis—We first examined the effects of PPARg (15dPGJ2 and
BRL49653) and PPARa (WY14643) ligands on DNA and colla-
gen synthesis by cultured HSC. 15dPGJ2 (10 mM), BRL49653
(10 mM), and WY14643 (250 mM) caused 40% inhibition in HSC
DNA synthesis (Fig. 4A). Collagen production as determined by
[3H]proline incorporation into collagenase-sensitive peptides
FIG. 2. A, PPARg mRNA is reduced in HSC from 7-day BDL animals.
RT-PCR demonstrates moderately reduced mRNA expression of PPARg
in HSC from the 7-day BDL animals, whereas induction of activation
marker genes such as a1(I) procollagen (a1(I) Coll) and a-SMA are
evident in these cells. B, both PPARa and PPARg are suppressed in
HSC from 19-day BDL animals. RT-PCR was performed as above on
HSC RNA samples from rats 19 days after sham or BDL operation.
Note the consistent reduction in the mRNA level of PPARa and PPARg
in HSC from BDL animals. C, semi-quantitative densitometric analysis
of the RT-PCR data depicting significantly (*, p , 0.05) decreased
mRNA levels of PPARa and PPARg in HSC from 19-day BDL animals.
FIG. 3. PPRE binding is diminished in HSC from 19-day BDL
animals. Nuclear extracts (10 mg of protein per sample) from HSC
isolated from 19-day sham or BDL animals were analyzed by electro-
phoretic mobility shift assay for binding to PPRE, NF-kB, or AP-1 site
as described under “Materials and Methods.” Note PPRE binding is
diminished in HSC from BDL animals, whereas NF-kB and AP-1 bind-
ing are enhanced. The last lane of the upper panel shows a supershift
assay with anti-PPARg antibodies, resulting in diminution of the bind-
ing by the sham HSC nuclear extracts and the appearance of a super-
shifted band (arrow). The use of non-immune antibodies did not affect
the binding pattern (data now shown N.S. refers to nonspecific binding).
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was also inhibited 75% by 15dPGJ2 or BRL49653 (10 mM) and
45% by WY14643 at 100 mM (Fig. 4B). The inhibition by
BRL49653 was also shown to be dose-dependent. Furthermore,
the involvement of PPARg in 15dPGJ2-mediated inhibition of
collagen production was supported by prevention of the
15dPGJ2 effect by a PPAR antagonist (GW9662) (Fig. 4C, lower
panel). As shown in the upper panel of Fig. 4C, GW9662 also
effectively blocked 15dPGJ2-mediated suppression of the rela-
tive collagen production (the percent of collagen production to
total protein synthesis), indicating the selectivity of collagen
synthesis inhibition by 15dPGJ2 is also dependent on PPARg.
It was also important to note that WY14643 produced the
inhibitory effects at the concentrations known to activate both
PPARa and -g (.100 mM) but not at those that only activate
PPARa (,10 mM); EC50 for mouse PPARa and -g are 0.6 and 30
mM, respectively (see Ref. 34 for review). In addition, a syn-
thetic PPARa-selective ligand (GW9578) failed to inhibit HSC
collagen synthesis (data not shown). Thus, the observed inhi-
bition with WY14643 likely reflects a PPARg-mediated effect.
Effects of 15dPGJ2 and WY14643 on HSC Activation Marker
Genes—To further examine the effects of PPAR ligands, mRNA
expression of HSC activation maker genes was screened by
semi-quantitative RT-PCR after treatment of the cells with
15dPGJ2 and WY14643. 15dPGJ2 (10 mM) caused conspicuous
and consistent suppression of a1(I) collagen and a-SMA mRNA
expression in HSC treated with or without TNFa (Fig. 5A).
MCP-1 expression was also moderately inhibited by the treat-
ment with 15dPGJ2 (Fig. 5A). These inhibitory effects were not
due to general and systematic suppression of the cellular func-
tions, since MMP-3 and CD36 were induced by the same treat-
ment (Fig. 5, A and B). Treatment with WY14643 (250 mM) also
reduced a1(I) collagen and a-SMA mRNA levels (Fig. 5C).
TNFa-induced MCP-1 mRNA expression was also suppressed
by WY14643 (Fig. 5C). Interestingly, WY14643 did not induce
MMP-3 expression but increased MMP-13 mRNA level (Fig.
5C). CD36 was not induced by WY14643 (data not shown).
Thus, these findings demonstrate the following. 1) 15dPGJ2
and WY14643 inhibit HSC collagen expression at the pretrans-
lational level, 2) other HSC activation markers such as en-
hanced DNA synthesis, expression of a-SMA and MCP-1, are
also inhibited by the treatments, 3) different MMPs are in-
duced by 15dPGJ2 and WY14643, and 4) 15dPGJ2 induces HSC
expression of CD36, a scavenger receptor, whose promoter con-
tains PPRE (43).
Effects of 15dPGJ2 and BRL49653 on Collagen Gene Promot-
er—To further examine the mechanism underlying inhibition
of HSC collagen gene expression by 15dPGJ2 and BRL49653,
we co-transfected HSC with an a1(I) collagen promoter-lucif-
erase construct (pGLCOL2) and a PPARg expression vector
and exposed the cells to the respective ligand. As shown in Fig.
6, 15dPGJ2 and BRL49653 inhibited the promoter activity by
60 and 50%, respectively. These results suggest that the dem-
onstrated inhibition of HSC collagen expression with the
PPARg ligands is mediated at least in part via the transcrip-
tional effects.
Morphological Changes Induced by 15dPGJ2—Since PPAR
ligands inhibited biochemical changes that are characteristic of
FIG. 4. A, PPARg (15dPGJ2, BRL49653) ligands inhibit HSC DNA
and collagen synthesis. The 3–4-day primary cultures of HSC were
exposed to 15dPGJ2 (1 and 10 mM), BRL49653 (1 and 10 mM), or
WY14643 (10;250 mM) for 18 h, and [3H]thymidine incorporation into
DNA was assessed. Note a significant, ;40%, inhibition in HSC DNA
synthesis by 15dPGJ2 and BRL49653 at 10 mM and WY14643 at 100
and 250 mM. *, p , 0.05; **, p , 0.01 compared with the respective
control. DMSO, Me2SO. B, collagen production by cultured HSC, as
determined by incorporation of [3H]proline into collagenase-sensitive
peptides was significantly inhibited by 18 h of treatment with 15dPGJ2
(10 mM), BRL49653 (0.1;10 mM), and WY14643 (100 mM). *, p , 0.05; **,
p , 0.01. C, the inhibitory effect on HSC collagen production by
15dPGJ2 is PPARg-dependent. A PPARg antagonist (GW9662) was
added 1 h before incubation with 15dPGJ2 for 18 h. Note this antago-
nist eliminated the 15dPGJ2-mediated inhibition of collagen production
by 75% (lower panel), supporting the role of PPARg in this regulation.
The upper panel depicts 15dPGJ2 as selectively inhibiting collagen
synthesis, as shown by a significant decrease in relative collagen pro-
duction (the percent of collagen production to total protein production)
and that this selective inhibition was abrogated by GW9662.
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HSC activation, we also examined whether 15dPGJ2 or
BRL49653 affected morphological features of HSC activation.
Culture-activated HSC demonstrated a flattened spread shape,
prominent actin stress fibers, and archetypal arrowhead-
shaped focal adhesion complexes, as described previously (16).
HSC treated with 10 mM 15dPGJ2 (Fig. 7) or 10 mM BRL49653
(data not shown) appeared somewhat less spread-out and had
mildly diminished stress fibers and focal adhesion complexes
without any signs of cytotoxicity. These results suggest that the
PPARg ligands may modulate activation-associated alterations
in the actin cytoskeleton and morphology of HSC.
Culture Activation and TNFa Suppress PPARg Expression,
and 15dPGJ2 Abrogates This Inhibition—We then questioned
whether culture-activated HSC also have reduced expression of
PPARg as in HSC from BDL animals. As shown in Fig. 8A,
RT-PCR (30 cycles of amplification) of RNA freshly isolated and
cultured HSC revealed a rapid decline in PPARg expression in
HSC cultured on plastic for 3 days, the time point when HSC
began myofibroblastic activation. Suppressed PPARg expres-
sion was sustained on day 7. However, the treatment of the
7-day cultured HSC with 15dPGJ2 (10 mM) for 18 h caused
restoration of PPARg expression (last lane), suggesting tran-
scriptional induction of this gene containing functional PPRE.
Next we questioned why PPARg expression was suppressed in
the in vivo activated HSC from BDL animals (Figs. 2 and 3).
TNFa is known to inhibit PPARg mRNA expression and ex-
pression of other adipocyte-specific genes in 3T3-L1 adiocytes
(45). Expression of this cytokine is induced in liver injury
including cholestatic liver injury (39). Furthermore, TNFa also
appears to play a role in the early phase of HSC activation in
liver fibrogenesis (46). Thus, we tested whether PPARg mRNA
expression was inhibited by TNFa and how 15dPGJ2 affected
this regulation in 3-day cultures of HSC. Using 35 cycles of
PCR, PPARg was sufficiently amplified to show a more distinct
band in these cells (Fig. 8B, first and second lanes) as compared
with Fig. 8A. TNFa inhibited basal mRNA expression of
PPARg (Fig. 8B, fifth and sixth lanes as compared with first
and second lanes). However the concomitant treatment of the
cells with 15dPGJ2 abrogated this inhibition (seventh and
eighth lanes). The same TNFa treatment did not result in
apparent changes in PPARa mRNA level, as assessed by the
semi-quantitative RT-PCR (data not shown).
DISCUSSION
This study demonstrated that PPARg expression and PPRE
binding were diminished in HSC as they underwent myofibro-
blastic activation in experimental cholestatic liver fibrosis in a
somewhat analogous manner to transdifferentiation of 3T3-L1
adipocytes to fibroblasts. However, HSC were shown to lack
expression of either adipocyte-specific PPARg2 isoform (Fig. 1)
or adipocyte-specific genes such as aP2,2 providing weak sup-
port to the hypothesis that HSC share the adipocyte phenotype.
Furthermore, in vivo activation of HSC was also accompanied
by reduced expression of PPARa, a transcription factor mostly
involved in regulation of genes encoding enzymes for fatty acid
metabolism. Even though these findings only showed the asso-
ciation, our in vitro findings served as direct evidence for the
regulatory role of PPAR in HSC activation. In culture-activated
HSC, the ligands for PPARg (15dPGJ2, BRL49653) and
WY14643 at the concentrations that activate both PPARa and
-g consistently reversed biochemical changes that were char-
acteristic of HSC activation. Since 15dPGJ2 is known to have
PPAR-independent effects (47, 48), we tested whether the sup-
pressive effect of 15dPGJ2 on HSC collagen synthesis was
mediated via PPARg by using an irreversible PPARg ligand
(GW9662), which works as an effective antagonist for PPARg
2 T. Miyahara, S. Xiong, and H. Tsukamoto, unpublished data.
FIG. 6. Inhibition of a1(I) collagen gene promoter with
15dPGJ2 and BRL49653. Cultured HSC after the first passage were
co-transfected with an a1(I) collagen promoter and a PPARg expression
vector and exposed to 15dPGJ2 (10 mM) or BRL49653 (10 mM). Lucifer-
ase activities were normalized by protein concentrations and expressed
as the relative expression to that without ligand treatment. Note sig-
nificant, 60 and 50%, reductions in the promoter activity caused by
15dPGJ2 and BRL49653, respectively.
FIG. 5. Suppression of activation marker genes in cultured
HSC with 15dPGJ2 or WY14643. A, messenger RNA expression for
a1(I) procollagen (a1(I)Coll), a-SMA, and MCP-1 is inhibited by
15dPGJ2 (10 mM), whereas MMP-3 was induced by the ligand in the
3–4-day-cultured HSC (left panel). The cells treated with TNFa re-
sponded similarly to 15dPGJ2 (right panel). B, expression of CD36 was
induced in 15dPGJ2-treated HSC as compared with the cells treated
with a vehicle control (Me2SO (DMSO)). C, WY14643 (100 mM) sup-
pressed a1(I) procollagen and a-SMA mRNA expression but induced
MMP-13 expression by cultured HSC. DMSO, Me2SO.
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(33, 34). Indeed, GW9662 eliminated the 15dPGJ2-mediated
inhibition by 70%, supporting the involvement of PPARg in this
effect. Besides collagen synthesis, the inhibitory effects by the
ligands were seen on many key parameters of HSC activation,
including DNA synthesis, mRNA expression for a1(I) collagen,
a-SMA, and MCP-1, and collagen promoter activity. We care-
fully ruled out the potential cytotoxic effects of the ligands by
performing the sensitive staining for necrosis and apoptosis.
The concentrations of the ligands used caused no cell death. We
also identified the genes such as MMPs and CD36 that were
induced in cultured HSC treated with the ligands, supporting
the fact that the cells were not under cytotoxic conditions.
Differential effects were seen with 15dPGJ2 and WY14643 on
induction of MMP-3 and MMP-13. The reason for this differ-
ence is unknown at the present time, and induction at the
protein level was not ascertained in this study. However, if the
observed induction of MMP-13 is confirmed at the protein and
activity levels, this indicates that WY14643 has dual inhibitory
effects on liver fibrogenesis via inhibition of collagen produc-
tion and stimulation of matrix degradation. Interpretation of
the induced MMP-3 by 15dPGJ2 is more complicated since it
may signify the initiation of degradation of the normal matrix
in the perisinusoidal space while it may also serve as an anti-
fibrotic effect via degradation of increased deposition of MMP-3
sensitive matrix components in liver fibrosis.
Induction of CD36 by 15dPGJ2 is intriguing. CD36 is a
membrane glycoprotein expressed by macrophages, adipocytes,
endothelial cells, smooth muscle cells, and many other cell
types that participates in uptake of oxidized low density li-
poprotein (43), long chain fatty acids (49), thrombospondin-1
binding (50), as well as phagocytosis of apoptotic cells (51).
Oxidized low density lipoprotein is considered to contain
PPARg ligands, and once internalized, they may serve to acti-
vate PPARg-RXR to further induce CD36 (43) and to inhibit the
activated phenotype of HSC. On the other hand, this inhibition
may also be opposed by the effects by lipid peroxides and
aldehydes liberated from oxidized low density lipoprotein,
which are known to induce oxidative stress and to signal for
activation of HSC (52). At the same time, induction of CD36
may enhance uptake of long chain fatty acids, potentially pro-
moting lipid storage. The functional consequence of PPARg
ligand-induced up-regulation of CD36 in HSC needs to be ad-
dressed in future studies by performing careful kinetic studies
on the effects of oxidized low density lipoprotein and unoxi-
dized fatty acids.
The present study demonstrated that PPARg ligands inhib-
ited collagen gene expression at least in part through inhibition
of collagen gene promoter activity. The mechanisms of this
transcriptional inhibition are unknown. However, a PPARa
ligand (WY14643) but not a PPARg ligand (BRL49653) was
recently shown to inhibit interleukin-1-induced expression of
interleukin-6 and COX-2 by human smooth muscle cells via
repression of NF-kB (44). Similar negative cross-coupling of
NF-kB, AP-1, or STAT activities in monocyte/macrophage cell
lines has been demonstrated by 15dPGJ2 and BRL49653 (42).
Thus, the observed inhibitory effects of PPARg ligands in the
present study may also be mediated via PPARg-mediated an-
tagonism on transcription factors that drive the collagen gene
promoter. Alternatively, the antagonism may be mediated by
the effects of the ligands on the upstream-signaling mecha-
nisms leading to the observed repression of the collagen gene
promoter. In fact, troglitazone, a synthetic PPARg ligand, in-
hibits mitogen-activated protein kinase activity when it sup-
presses DNA synthesis and migration of vascular smooth mus-
cle cells (53). In a recent study testing PPAR ligands on colonic
epithelial cells, 15dPGJ2 treatment was shown to prevent in-
terleukin-1b-induced IkB-a degradation, suggesting the up-
stream inhibitory effect of the ligand (54). In fact, this effect
may be due to direct inhibition of IkBkinase independent of
FIG. 7. Morphological changes in
cultured HSC exposed to 15dPGJ2.
Representative differential interference
contrast and fluorescent images of the
7-day-cultured HSC exposed to the car-
rier (A, B, and C) or 10 mM (D, E, and F)
15dPGJ2. Differential interference con-
trast images are presented in the left col-
umn (A and D). Cells stained for actin
stress fibers are displayed in the middle
column (B and E); cells stained for focal
adhesion complexes are displayed in the
right column (C and F).
FIG. 8. Culture activation and TNFa suppress PPARg mRNA
expression by HSC and 15dPGJ2 abrogates this effect. A, RT-PCR
analysis (30 cycles of amplification) of RNA from freshly isolated and
cultured HSC demonstrates a rapid decline in PPARg expression in
culture for 3 days and sustained suppression of the gene on day 7. The
treatment of the 7-day-cultured HSC with 15dPGJ2 (10 mM) for 18 h
caused restoration at PPARg expression (last lane). B, RT-PCR analysis
(35 cycles of amplification) of RNA from the 3–4-day-cultured HSC
exposed to TNFa without or with 15dPGJ2. The treatment of the 3–4-
day HSC cultures with TNTa (10 ng/ml) further inhibited PPARg
expression (lane 5 and 6). However, the concomitant treatment of the
cells with 15dPGJ2 abrogated this inhibition (lanes 7 and 8).
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PPARg (47, 48). Future studies will characterize locations of
upstream signaling affected by the PPARg ligands as well as
the elements within the promoter that are responsible for the
repressive effects of the ligands.
Our results also provided the in vitro evidence for the poten-
tial role of TNFa in suppression of PPARg expression in HSC
as we observed in vivo. The similar effect was previously shown
in 3T3-L1 adipocytes, in which a time- and concentration-de-
pendent decrease in PPARg mRNA expression was observed
after TNFa treatment, the effect considered as the biochemical
basis for anti-adipogenic effects of TNFa (45). It remains to be
tested whether TNFa is indeed responsible for PPARg repres-
sion observed in HSC in cholestatic liver fibrosis. It should be
noted that growth factors such as epidermal growth factor and
platelet-derived growth factor are also capable of inhibiting
PPARg expression via mitogen-activated protein kinase-medi-
ated phosphorylation of PPARg (55). Since both TGF-a and
platelet-derived growth factor are implicated in HSC activation
as autocrine and paracrine mitogens (1, 8, 46), we cannot rule
out the role of these growth factors in PPARg inhibition in vivo.
Remarkably, the concomitant treatment of HSC with 15dPGJ2
completely abrogated the TNFa-induced suppressive effect on
PPARg. This ligand also restored PPARg mRNA expression in
culture-activated HSC that showed a rather rapid decline in
expression of this transcription factor. In fact, we believe this
induction by 15dPGJ2 facilitated the responsiveness of cul-
tured HSC to the ligand, as demonstrated by suppressed ex-
pression of activation marker genes (collagen, a-SMA, MCP-1)
and induction of CD36 and MMPs. These findings further
suggest that 15dPGJ2 and other PPARg ligands may serve as
effective anti-fibrotic agents, since it normalizes PPARg ex-
pression while suppressing the activation marker genes at the
same time. Alternatively, we could interpret that the latter
effect is a consequence of the former effect. The normalized
level of endogenous PPARg likely transduces better anti-fi-
brotic effects of the endogenous or exogenous ligands, espe-
cially when the HSC content of RXR and 9-cis RA, the active
partner/ligand for PPARg, is depleted as in liver fibrosis (22).
In vivo effects of PPARg ligands on development and progres-
sion of liver fibrosis are currently being investigated.
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